Systematic review and meta-analysis of the efficacy of statins in experimental stroke

International Journal of Stroke

Volumn 7, Issue 2, 2012, Pages 150-156

  Baryan, Hardaman K ^a   Allan, Stuart M ^a   Vail, Andy ^a   Smith, Craig J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Meta analysis; Neuroprotection; Preclinical; Statins; Stroke; Systematic review

Indexed keywords

FLUINDOSTATIN; PRAVASTATIN; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN INFARCTION SIZE; DRUG EFFICACY; EXPERIMENTAL FOCAL CEREBRAL ISCHEMIA; FOCAL CEREBRAL ISCHEMIA; INFORMATION RETRIEVAL; META ANALYSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLOGICAL SEVERITY SCORE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; REVIEW; STROKE; SYSTEMATIC REVIEW;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFARCTION, MIDDLE CEREBRAL ARTERY; RESEARCH DESIGN; STROKE;

EID: 84862929090     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00740.x     Document Type: Review

References (43)

1. O'Collins V, Macleod M, Donnan G, Horky L, van der Worp B, Howells D. 1026 experimental treatments in acute stroke. Ann Neurol 2006; 59 : 467-477.
2. Sena E, van der Worp H, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 2007; 30 : 433-439.
3. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87 : 179-197.
4. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30 : 2752-2758.
5. Banwell V, Sena E, Macleod M. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis 2009; 18 : 269-276.
6. Sandercock P, Roberts I. Systematic reviews of animal experiments. Lancet 2002; 360 : 586.
7. Sena E, Wheble P, Sandercock P, Macleod M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke 2007; 38 : 388-394.
8. Endres M, Laufs U, Huang Z etal. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998; 95 : 8880-8885.
9. Balduini W, Mazzoni E, Carloni S etal. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 2003; 34 : 2007-2012.
10. Sironi L, Cimino M, Guerrini U etal. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003; 23 : 322-327.
11. van der Most P, Dolga A, Nijholt I, Luiten P, Eisel U. Statins: mechanisms of neuroprotection. Prog Neurobiol 2009; 88 : 64-75.
12. Fisher M, Feuerstein G, Howells D etal. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40 : 2244-2250.
13. Macleod M, O'Collins T, Howells D, Donnan G. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004; 35 : 1203-1208.
14. Gerriets T, Stolz E, Walberer M etal. Noninvasive quantification of brain edema and the space-occupying effect in rat stroke models using magnetic resonance imaging. Stroke 2004; 35 : 566-571.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315 : 629-634.
16. Sterne J, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54 : 1046-1055.
17. Berger C, Xia F, Maurer MH, Schwab S. Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev 2008; 58 : 48-56.
18. Chen J, Zacharek A, Ll A etal. Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience 2006; 141 : 737-744.
19. Chen J, Zhang C, Jiang H etal. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005; 25 : 281-290.
20. Chen J, Zhang ZG, Li Y etal. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53 : 743-751.
21. Cui X, Chopp M, Zacharek A etal. Chemokine, vascular and therapeutic effects of combination simvastatin and BMSC treatment of stroke. Neurobiol Dis 2009; 36 : 35-41.
22. Elewa HF, Kozak A, El-Remessy AB etal. Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J Pharmacol Exp Ther 2009; 330 : 532-540.
23. Kilic U, Bassetti CL, Kilic E, Xing H, Wang Z, Hermann DM. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience 2005; 134 : 901-906.
24. Kilic E, Kilic U, Matter CM, Luescher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke 2005; 36 : 332-336.
25. Nagaraja TN, Knight RA, Croxen RL, Konda KP, Fenstermacher JD. Acute neurovascular unit protection by simvastatin in transient cerebral ischemia. Neurol Res 2006; 28 : 826-830.
26. Prinz V, Laufs U, Gertz K etal. Intravenous rosuvastatin for acute stroke treatment - an animal study. Stroke 2008; 39 : 433-438.
27. Shimamura M, Sato N, Sata M etal. Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke 2007; 38 : 3251-3258.
28. Sugiura S, Yagita Y, Sasaki T etal. Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion. Brain Res 2007; 1181 : 125-129.
29. Wang L, Zhang X, Liu L, Yang R, Cui L, Li M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF kappaB expression. Neurosci Lett 2010; 471 : 152-156.
30. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG. Atorvastatin extends the therapeutic window for tPA to 6h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 2009; 29 : 1816-1824.
31. Zhang L, Zhang ZG, Liu XS, Hozeska-Solgot A, Chopp M. The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat. Arterioscler Thromb Vasc Biol 2007; 27 : 2470-2475.
32. Zhang L, Zhang ZG, Ding GL etal. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005; 112 : 3486-3494.
33. Sironi L, Banfi C, Brioschi M etal. Activation of NF-kB and ERK 1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol Dis 2006; 22 : 445-451.
34. Ding G, Jiang Q, Li L etal. MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin. J Neurol Sci 2006; 246 : 139-147.
35. Minnerup J, Heidrich J, Rogalewski A, Schäbitz W, Wellmann J. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009; 40 : 3113-3120.
36. Macleod M, van der Worp H, Sena E, Howells D, Dirnagl U, Donnan G. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008; 39 : 2824-2829.
37. Minnerup J, Heidrich J, Wellmann J, Rogalewski A, Schneider A, Schäbitz W. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 2008; 39 : 1855-1861.
38. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005; 36 : 1298-1300.
39. National collaborating centre for chronic conditions. Stroke: National Clinical Guideline for Diagnosis and Initial Management of Acute Stroke and Transient Ischaemic Attack (TIA). London, Royal college of physicians. National Institute for Health and Clinical Excellence, (Internet) July 2008. Available at (accessed May 2010).
40. Montaner J, Chacón P, Krupinski J etal. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008; 15 : 82-90.
41. Clinicaltrials.Gov. A service of the U.S. National Institutes of Health: stroke treatment with acute reperfusion and simvastatin [clinicaltrials.Gov identifier: NCT01073007], (Internet) February 2010. Available at (accessed May 2010).
42. Elkind M, Sacco R, Macarthur R etal. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009; 28 : 266-275.
43. The Internet Stroke Centre. Stroke Trials Registry: (NeuSTART II) Neuroprotection with statin therapy for acute recovery trial (Neu START): a phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke [SPOTRIAS], (Internet) 2010 Available at (accessed May 2010).